Huntington's disease: disappointments and new beginnings
- PMID: 35716683
- DOI: 10.1016/S1474-4422(22)00189-2
Huntington's disease: disappointments and new beginnings
Conflict of interest statement
CS received honorarium from Temmler GmbH, Desitin Arzneimittel GmbH, and Teva Pharmaceuticals for scientific talks. CS also received travel or accommodation payments in the context of the Registry study of the European Huntington's Disease Network, the MitoNet study, the ENROLL HD study (CHDI Foundation), the ACR16 study (Neurosearch), the AFQ study (Novartis), the Selisistat studies (Siena Biotech), the PRIDE-HD study (Teva Pharmaceuticals), the Amaryllis-study (Pfizer), the PROOF-HD study (Prilenia). CS has also received payments in the context of the CS1 ISIS-443139 ASO study (Ionis Pharmaceuticals), the PRECISION-HD1 study (Wave Life Sciences), the PRECISION-HD2 study (Wave Life Sciences), the SELECT-HD study (Wave Life Sciences), the RG6042 ASO GenExtend study (Roche), the GenerationHD1 study (Roche), the CS2 study (Roche), and the NHS study (Roche). CS has also received research support for a research project with Teva GmbH, Biogen, Huntington-Stiftung, and the CHDI Foundation.
Comment on
-
A biological classification of Huntington's disease: the Integrated Staging System.Lancet Neurol. 2022 Jul;21(7):632-644. doi: 10.1016/S1474-4422(22)00120-X. Lancet Neurol. 2022. PMID: 35716693 Review.
-
Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities.Lancet Neurol. 2022 Jul;21(7):645-658. doi: 10.1016/S1474-4422(22)00121-1. Lancet Neurol. 2022. PMID: 35716694 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical